Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma
{{output}}
Background: The KEYNOTE-522 (KN522) trial demonstrated significantly improved outcomes with neoadjuvant chemotherapy (NAC) combined with pembrolizumab in high-risk triple-negative breast cancer (TNBC). However, the efficacy of th... ...
